Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders

1. A method for detecting an inflammatory disease in a subject, comprising:

(a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from said subject; and

(b) comparing the level of expression of said one or more inflammatory disease markers in said biological sample to a normal level of expression of said one or more inflammatory disease markers,

wherein a higher than normal level of expression of one or more of said plurality of inflammatory disease markers in said biological sample is indicative of the presence of an inflammatory disease in said subject, wherein said normal levels of expression of said plurality of inflammatory disease markers is a predetermined value, and wherein said one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5 and

wherein said one or more inflammatory disease markers further comprise one or more antibodies directed against, and/or one or more antigens derived from, inflammation-related microorganisms selected from the group consisting of Mycobacterium, Bacteroides, Brucella, Campylobacter, Escherichia coli, Saccharomyces cerevisiae, Klebsiella, Yersinia pseudotuberculosis, Clostridium, Enterococcus, Eubacterium, Listeria monocytogenes, Peptostreptococcus, Helicobacter, Haemophilus influenzae, Pseudomanas fluorescens, Salmonella, Chlamydia , human hepatitis virus and human rhinovirus.

2. The method of claim 1 , wherein said one or more inflammatory disease markers further comprise one or more markers selected from the group consisting of: CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL17, CCL20, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, XCL1, CX3CL1, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR4, XCR1.

3. The method of claim 1 , wherein said one or more inflammatory disease markers further comprise one or more markers selected from the group consisting of: leptin, tumor necrosis factor α (TNFα), interferon-γ (IF-γ), interleukin-1α (IL-1α), IL-1β, IL-6, IL-12, IL-17, and IL-23.

4. The method of claim 1 , wherein said inflammatory disease is selected from the group consisting of anaphylaxis, septic shock, septic arthritis, rheumatoid arthritis, psoriatic arthritis, asthma, delayed type hypersensitivity, dermatitis, diabetes mellitus, juvenile onset diabetes, graft rejection, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, enteritis, interstitial cystitis, multiple sclerosis, myasthemia gravis, Grave's disease, Hashimoto's thyroiditis, pneumonitis, nephritis, pneumonitis, obstructive pulmonary disease, bronchitis, bronchitis rhinitis, spondyloarthropathies, scleroderma, systemic lupus erythematosus, and hepatitis.

5. The method of claim 1 , wherein said biological sample is a plasma sample, a saliva sample, synovial fluid sample, a urine sample, or a fecal sample.

6. The method of claim 1 , wherein said detecting step comprises contacting said biological sample with one or more binding agents that bind specifically to said one or more inflammatory disease markers.

7. The method of claim 6 , wherein said one or more binding agents bind to said one or more inflammatory disease markers with kd value in the range of 0.01 pM to 1 μM.

8. The method of claim 6 , wherein said binding agents comprise one or more peptides or polypeptides.

9. The method of claim 8 , wherein the binding agents comprise one or more antibodies, peptide aptamers, and/or synbodies.

10. The method of claim 1 , wherein said one or more inflammatory disease markers comprise:

(1) at least one inflammatory disease marker selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5;

(2) at least one inflammatory disease marker selected from the group consisting of CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL17, CCL20, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, XCL1, CX3CL1, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR4, XCR1; and

(3) at least one inflammatory disease marker selected from the group consisting of leptin, tumor necrosis factor α (TNFα), interferon-γ (IF-γ), interleukin-1α (IL-1α), IL-1β, IL-6, IL-12, IL-17, and IL-23.

11. The method of claim 1 , wherein said inflammatory disease is arthritis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CXCL12, CCL20, XCL1, CX3CL1, CXCR4, CXCR5, CCR6, XCR1, CX3CR1.

12. The method of claim 1 , wherein said inflammatory disease is asthma and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL3, CCL4, CCL5, CCL7, CCL8, CCR3, CCR4, CCR5, CCL11, CCL15, CCL17, CCL22, CCL24, and CCL26.

13. The method of claim 1 , wherein said inflammatory disease is septic shock or anaphylaxis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CCL5, CXCR1, and CXCR2.

14. The method of claim 1 , wherein said inflammatory disease is diabetes and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL2, CCL9, CX3CL1, CCR2, CCR4, and CX3CR1.

15. The method of claim 1 , wherein said inflammatory disease is dermatitis or delayed-type hypersensitivity and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL2, CCL3, CCL4, CCL5, CCL17, CCL29, CCL22, CCL27, CCR4, CCR5, CCR6, and CCR10.

16. The method of claim 1 , wherein said inflammatory disease is graft rejection and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL3, CCL4, CCL5, XCL1, CCR5, and XCR1.

17. The method of claim 1 , wherein said inflammatory disease is multiple sclerosis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL3, CCL4, CCL5, CCL7, CCL14, CCL15, CCL23, CCR1, and CCR5.

18. The method of claim 1 , wherein said inflammatory disease is mysasthemia gravis, Grave's disease or Hashimoto thyroiditis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL3, CCL4, CCL5, XCL1, CCR5, and XCR1.

19. The method of claim 1 , wherein said inflammatory disease is nephritis or systemic lupus ethematosus and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL2, CCL3, CCL4, CCL5, CCL8, CCL12, CCL13, CX3CL1, CCR2, CCR4, and CX3CR1.

20. The method of claim 1 , wherein said inflammatory disease is pneumonitis, chronic obstructive pulmonary disease (COPD) or chronic bronchitis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CXCL1, CXCL2, CXCL3, CXCL5, CXCL7, CXCL8, CCL3, CCL5, CCL7, CCL8, CCL11, CCL13, CCL24, CCL26, CXCR2, and CCR3.

21. A method for monitoring the course of treatment for an inflammatory disease in a subject, comprising:

determining the expression levels of one or more inflammatory disease markers in one or more biological samples obtained from said subject during or after said treatment; and

comparing the level of expression of said one or more inflammatory disease markers in said one or more biological samples to a control level of expression of said one or more inflammatory disease markers,

wherein said control level of said one or more inflammatory disease markers is a pre-treatment level of said one or more inflammatory disease markers in said subject or a predetermined reference level,

wherein said treatment is deemed efficacious if the levels of expression of said one or more inflammatory disease markers in said one or more biological samples obtained from said subject during or after said treatment are similar to, or lower than, said control level,

wherein said one or more inflammation markers comprise one or more inflammatory disease markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5.

22. A method for detecting an inflammatory disease in a subject, comprising:

(a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from said subject; and

(b) comparing the level of expression of said one or more inflammatory disease markers in said biological sample to a normal level of expression of said one or more inflammatory disease markers,

wherein a higher than normal level of expression of one or more of said plurality of inflammatory disease markers in said biological sample is indicative of the presence of an inflammatory disease in said subject, wherein said normal levels of expression of said plurality of inflammatory disease markers is a predetermined value, and wherein said one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5, and

wherein said one or more inflammatory disease markers further comprise:

(1) at least one inflammatory disease marker selected from the group consisting of CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL17, CCL20, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, CXCL12, XCL1, CX3CL1, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR4, XCR1; leptin, tumor necrosis factor α (TNFα), interferon-γ (IF-γ), interleukin-1α (IL-1α), IL-1β, IL-6, IL-12, IL-17, and IL-23; and

(2) at least one antibody directed against an inflammation-related microorganism selected from the group consisting of Mycobacterium, Bacteroides, Brucella, Campylobacter, Escherichia coli, Saccharomyces cerevisiae, Klebsiella, Yersinia pseudotuberculosis, Clostridium, Enterococcus, Eubacterium, Listeria monocytogenes, Peptostreptococcus, Helicobacter, Haemophilus influenzae, Pseudomanas fluorescens, Salmonella, Chlamydia , human hepatitis virus and human rhinovirus.

23. A method for detecting an inflammatory disease in a subject, comprising:

(a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from said subject; and

(b) comparing the level of expression of said one or more inflammatory disease markers in said biological sample to a normal level of expression of said one or more inflammatory disease markers,

wherein a higher than normal level of expression of one or more of said plurality of inflammatory disease markers in said biological sample is indicative of the presence of an inflammatory disease in said subject, wherein said normal levels of expression of said plurality of inflammatory disease markers is a predetermined value, and wherein said one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5, and

wherein said inflammatory disease is interstitial cystitis and wherein the one or more inflammatory disease markers further comprises one or more inflammatory disease markers selected from the group consisting of CCL3, CCL4, CCL5 and CCR5.